Cytek Biosciences, Inc.
NASDAQ:CTKB · NASDAQ Global Select
-$0.11 today
Vol 15.69M · Avg 0.88M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:CTKB · Revenue to Net Income
Key Ratios
Analysis
$204.2M of revenue converted into -$74.0M of net income for the selected period. Gross margin is 51.5% and net margin is -34.1%, showing how much revenue survives after costs and taxes. EPS is $-0.58, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $201.5M +0.5% | $200.5M +3.9% | $193.0M +17.7% | $164.0M +28.2% | $128.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $97.0M +8.6% | $89.3M +6.9% | $83.6M +32.6% | $63.1M +29.2% | $48.8M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $104.5M -6.0% | $111.1M +1.5% | $109.4M +8.4% | $101.0M +27.6% | $79.1M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 51.8% -3.6pp | 55.4% -1.3pp | 56.7% -4.9pp | 61.6% -0.3pp | 61.9% | 9.8% | 28.9% | 38.3% |
| Research & Development | $36.5M -7.4% | $39.4M -10.8% | $44.2M +26.7% | $34.9M +42.6% | $24.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $108.4M +17.5% | $92.2M -1.0% | $93.1M +37.1% | $67.9M +49.1% | $45.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $144.8M +10.0% | $131.6M -4.1% | $137.3M +33.6% | $102.8M +46.9% | $70.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $12.0M +14.2% | $10.5M +13.7% | $9.2M +63.1% | $5.7M +355.6% | $1.2M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$17.4M -463.1% | $4.8M +208.7% | -$4.4M -146.4% | $9.5M +6.4% | $8.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -8.6% -11.0pp | 2.4% +4.7pp | -2.3% -8.1pp | 5.8% -1.2pp | 7.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$40.4M -96.8% | -$20.5M +26.3% | -$27.8M -1443.5% | -$1.8M -119.7% | $9.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -20.0% -9.8pp | -10.2% +4.2pp | -14.4% -13.3pp | -1.1% -8.3pp | 7.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $2.2M -78.6% | $10.4M +61.5% | $6.4M +38.8% | $4.6M +9326.5% | $49.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $474.0K | $0 -100.0% | $2.1M -19.5% | $2.6M +47.8% | $1.7M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $10.5M -28.9% | $14.8M +22.1% | $12.1M +296.1% | $3.1M +195.2% | -$3.2M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$29.8M -423.5% | -$5.7M +63.7% | -$15.7M -1346.7% | $1.3M -78.8% | $5.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -14.8% -12.0pp | -2.8% +5.3pp | -8.1% -8.9pp | 0.8% -3.9pp | 4.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $36.7M +11368.1% | $320.0K +109.0% | -$3.6M -190.9% | -$1.2M -142.0% | $2.9M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$66.5M -1005.3% | -$6.0M +50.4% | -$12.1M -571.6% | $2.6M -14.2% | $3.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | -33.0% -30.0pp | -3.0% +3.3pp | -6.3% -7.9pp | 1.6% -0.8pp | 2.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -1030.4% | -$0 +48.8% | -$0 -567.7% | $0 -41.8% | $0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -1028.0% | -$0 +48.7% | -$0 -582.8% | $0 -43.6% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $127.7M -2.2% | $130.6M -3.5% | $135.3M +0.6% | $134.5M +0.6% | $133.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $127.7M -2.2% | $130.6M -3.5% | $135.3M -2.4% | $138.6M +3.6% | $133.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Avanos Medical, Inc.
NYSE:AVNS
$1.17B
CeriBell, Inc.
NASDAQ:CBLL
$666.01M
Surmodics, Inc.
SRDX
$614.51M
ClearPoint Neuro, Inc.
NASDAQ:CLPT
$529.62M
AngioDynamics, Inc.
NASDAQ:ANGO
$494.59M
OrthoPediatrics Corp.
NASDAQ:KIDS
$472.35M
Varex Imaging Corporation
NASDAQ:VREX
$442.89M
Standard BioTools Inc.
NASDAQ:LAB
$314.36M
Organogenesis Holdings Inc.
NASDAQ:ORGO
$309.46M
Treace Medical Concepts, Inc.
NASDAQ:TMCI
$263.71M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CTKB generate?
Cytek Biosciences, Inc. (CTKB) reported $201.49M of revenue in fiscal 2025.
Is CTKB profitable?
Cytek Biosciences, Inc. (CTKB) reported -$66,539,000.00 of net income, with a net margin of -33.0%.
Explore More
Continue the stock analysis
Jump to another research area for this company.